Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for refractory oral and ocular dryness in primary Sjogren syndrome
ChiCTR2200057578Phase 4Not yet recruiting
- Sponsor
- Ningbo Medical Centre Lihuili Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in primary Sjögren's syndrome (2 arms), sponsored by Ningbo Medical Centre Lihuili Hospital. Primary endpoints: Unstimulated whole saliva flow, Stimulated whole saliva flow and 5 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2200057578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057578.